AI Article Synopsis
- Retroperitoneal liposarcoma (RPLPS) is a rare and challenging cancer, especially when it's larger than 30 cm, which complicates diagnosis and treatment.
- A 58-year-old male was diagnosed with a giant RPLPS measuring 55 cm, which had invaded surrounding organs; he underwent successful surgical resection and was discharged with no recurrence after 6 months.
- Surgery is the most effective treatment for RPLPS, emphasizing the importance of detailed preoperative evaluations, while the necessity of additional therapies like radiotherapy or chemotherapy remains debated.
Article Abstract
Background: Retroperitoneal liposarcoma (RPLPS) is a relatively rare disease. Liposarcomas vary in size, but sizeable RPLPS larger than 30 cm in diameter are very rare, and their diagnosis and treatment present significant challenges.
Case Presentation: We report a 58-year-old male patient who was admitted to the hospital with an increased abdominal circumference and was later diagnosed with a giant RPLPS. The liposarcoma was found to adhere to the right kidney and the entire ureter, invading the ascending colon. The patient underwent complete combined surgical resection. The tumor was removed intact, measured 55.0 cm × 30.0 cm × 18.0 cm, and weighed 19.8 kg. Histopathologic analysis revealed well-differentiated liposarcoma (WDLPS). The patient was successfully discharged from the hospital and followed up for 6 months with no signs of recurrence.
Conclusion: RPLPS is a rare tumor with atypical clinical presentation. Surgery remains the most effective method of treatment for retroperitoneal sarcomas, with complete removal if there is local invasion. Preoperative examination, including three-dimensional (3D) reconstruction, is essential for surgical success. The role of adjuvant radiotherapy or chemotherapy remains controversial. However, clinicians should not rule them out as viable options.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363381 | PMC |
| http://dx.doi.org/10.1186/s12882-024-03701-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Author Reflections: Does Perioperative Radiotherapy have the Potential to Improve Disease-Specific Survival in Patients with Retroperitoneal Liposarcoma?
Ann Surg Oncol
January 2025
Department of Surgery, Clarunis - St. Clara Hospital & University Hospital Basel, Basel, Switzerland.
Introduction: Adrenal myelolipomas are uncommon benign adrenal tumors, which mostly occur unilaterally. We describe a rare case of giant bilateral adrenal myelolipoma mistaken for retroperitoneal liposarcoma.
Case Presentation: A 49-year-old man developed fever, left flank pain, and a large mass in his left abdomen.
Potential benefits of neoadjuvant radiotherapy prior to "en bloc" compartmental resection of pure retroperitoneal liposarcomas.
World J Urol
December 2024
Department of Urology and Kidney Transplantation, University Hospital of Rangueil, Toulouse, France.
Retroperitoneal liposarcomas(RPL) are rare malignant tumors, accounting for approximately 15% of soft tissue sarcomas and 0.07-0.2% of all cancers.
View Article and Find Full Text PDFTotal retroperitoneal lipectomy improves prognosis in patients with primary retroperitoneal liposarcoma: a comparative study.
Front Oncol
December 2024
Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China.
Background: Retroperitoneal liposarcoma (RPLS) is the most common soft tissue sarcoma originating in the retroperitoneal space. Although surgery is the standard treatment, recurrence remains frequent. In this study, we aimed to explore the safety and efficacy of total (ipsilateral) retroperitoneal lipectomy (TRL) compared to traditional complete resection (CR) for primary RPLS.
View Article and Find Full Text PDFIntegrated lipidomics and RNA-seq reveal prognostic biomarkers in well-differentiated and dedifferentiated retroperitoneal liposarcoma.
Cancer Cell Int
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, Beijing, 100142, P. R. China.
Background: Retroperitoneal liposarcoma (RLPS) is a mesenchymal malignant tumor characterized by different degrees of adipocytic differentiation. Well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are two of the most common subtypes of RLPS, exhibiting clear differences in biological behaviors and clinical prognosis. The metabolic features and genomic characteristics remain unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!